表皮生长因子受体与肿瘤治疗

EGFR for cancer treatment

表皮生长因子受体(EGFR)是一个家族,在不同肿瘤中均有高表达。EGFR活化会增加肿瘤细胞的增殖、侵袭、转移,因此EGFR的抑制剂成为重要的治疗肿瘤新药,EGFR成为治疗肿瘤的分子靶区。EGFR抑制剂包括小分子化合物和单克隆抗休两大类,临床试验表明在肿瘤治疗上两者都有很大价值。

EGFR (epidermal growth factor receptor) is a family which presents high expression in different cancers. The activation of EGFR promotes the proliferation, invasion and metastasis of cancer cells, then EGFR inhibitors may be important new drugs for treatment of human cancer, and EGFR is the molecular targets. EGFR inhibitors include small molecular compounds and monoclonal antibody. The results of a series clinical trials suggested that EGFR inhibitions have close relation to cancer treatment.